孙元珏.晚期软组织肉瘤新药临床应用进展[J].肿瘤学杂志,2017,23(11):959-966. |
晚期软组织肉瘤新药临床应用进展 |
Clinical Application Progress on New Drugs in Advanced Soft-tissue Sarcoma |
投稿时间:2017-01-22 |
DOI:10.11735/j.issn.1671-170X.2017.11.B005 |
|
|
中文关键词: 肿瘤,结缔和软组织 药物疗法 抗肿瘤药 |
英文关键词:neoplasms connective and soft tissue drug therapy antineoplastic agents |
基金项目: |
|
摘要点击次数: 2051 |
全文下载次数: 1973 |
中文摘要: |
摘 要:软组织肉瘤是一组来源于间叶组织的恶性肿瘤,病理类型繁多。对于不可切除的局部晚期或转移性软组织肉瘤,以姑息性化疗为主的多学科综合治疗有利于减轻患者症状、延长总生存期和提高生活质量。蒽环类药物和异环磷酰胺仍是软组织肉瘤化疗的基石,近年来曲贝替定、艾瑞布林等新型化疗药物和培唑帕尼、Olaratumab等分子靶向药物相继问世,获批用于晚期软组织肉瘤的内科治疗,免疫检查点抑制剂PD-1/PD-L1单抗的异军突起,更是给晚期软组织肉瘤的免疫治疗带来了新的曙光。 |
英文摘要: |
Abstract:Soft-tissue sarcomas(STS) are a group of malignant tumors derived from mesenchymal tissue with various pathological types. For unresectable locally advanced and metastatic soft-tissue sarcomas,palliative chemotherapy as an important role of multi-disciplinary comprehensive treatment is able to relieve symptoms,prolong the overall survival and improve the quality of life predominantly.Anthracycline-based drugs and ifosfamide still serve as the foundation of chemotherapy for soft-tissue sarcomas. In recent years,trabectedin,eribulin,pazopanib,olaratumab and other new types of anti-tumors drugs were approved for medical treatment in advanced soft-tissue sarcoma. The appearance of immune checkpoint inhibitors such as PD-1/PD-L1 monoclonal antibodies has also provided new prospect for immunotherapy of advanced soft-tissue sarcomas. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |